Safety and efficacy of rituximab treatment for vasculitis in hepatitis B virus-associated type II cryoglobulinemia: a case report

@inproceedings{Pasquet2012SafetyAE,
  title={Safety and efficacy of rituximab treatment for vasculitis in hepatitis B virus-associated type II cryoglobulinemia: a case report},
  author={Florian Pasquet and François Combarnous and Brigitte MacGregor and Brigitte Copp{\'e}r{\'e} and Christelle Mausservey and Jacques Ninet and Arnaud Hot},
  booktitle={Journal of medical case reports},
  year={2012}
}
INTRODUCTION Systemic B-cell depletion and clinical remission of the systemic effects of cryoglobulins have already been achieved using rituximab in hepatitis C virus-positive immunocompetent patients. Conversely, to the best of our knowledge there are no reports in the literature regarding the use of rituximab in hepatitis B virus-associated cryoglobulinemia. CASE PRESENTATION We report here the case of a 60-year-old Caucasian man who presented with hepatitis B virus-associated type II… CONTINUE READING
6 Citations
17 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 17 references

Mascia MT: Cryoglobulinemic vasculitis

  • C Ferri
  • Curr Opin Rheumatol
  • 2006
Highly Influential
6 Excerpts

Similar Papers

Loading similar papers…